Two years after Allergan snagged co-promotion rights to MAP Pharmaceuticals' inhalable migraine therapy Levadex with a $157 million licensing deal, it's come back to the bargaining table and crafted a pact to buy the biotech for close to a billion dollars.
Hours after the markets closed last night, Map Pharmaceuticals put out the word that the FDA had stiff-armed its application for the inhalable migraine therapy Levadex.
Those who suffer from migraines, and cannot find relief from traditional oral medication, might soon have another choice with an orally inhaled migraine drug. MAP Pharmaceuticals, a 2008 Emerging
Allergan has agreed to pay Map Pharmaceuticals $60 million upfront and promised up to $97 million more for the right to co-promote the new migraine drug Levadex, which is poised for a regulatory
Shares of MAP Pharmaceuticals slid nine percent on the news that AstraZeneca had pulled out of a collaboration with the developer on an experimental pediatric asthma therapy, forcing MAP to suspend
Shares of MAP Pharmaceuticals soared this morning on news that the company's inhalable migraine therapy Levadex (MAP0004) met all four primary endpoints in a Phase III study. Levadex achieved
MAP Pharma's shares tanked on the news that its late-stage asthma therapy for children flunked a Phase III trial. Its stock swiftly plunged 40 percent in overnight trading as investors digested the
AstraZeneca and MAP Pharmaceuticals have signed a development and commercialization deal covering Phase III asthma drug Unit Dose Budesonide (UDB), MAP's nebulized formulation of budesonide. MAP gets
Mountain View, CA-based MAP Pharmaceuticals announced that it is planning an IPO of 5 million shares of common stock at a price of between $14 and $16 per share. Money raised from the offering will
San Jose, CA-based MAP Pharmaceuticals has raised $25.5 million in its third round of venture capital. Most of the money is earmarked for pushing the development of new therapies for asthma and